Quantitative and qualitative evaluation of liver metastases with intraprocedural cone beam CT prior to transarterial radioembolization as a predictor of treatment response

Florian Messmer MD , Juliana Zgraggen , Adrian Kobe MD , Lyubov Chaykovska MD , Gilbert Puippe MD , Caecilia S. Reiner MD , Thomas Pfammatter MD
{"title":"Quantitative and qualitative evaluation of liver metastases with intraprocedural cone beam CT prior to transarterial radioembolization as a predictor of treatment response","authors":"Florian Messmer MD ,&nbsp;Juliana Zgraggen ,&nbsp;Adrian Kobe MD ,&nbsp;Lyubov Chaykovska MD ,&nbsp;Gilbert Puippe MD ,&nbsp;Caecilia S. Reiner MD ,&nbsp;Thomas Pfammatter MD","doi":"10.1016/j.redii.2022.100005","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>To investigate, by quantitative and qualitative enhancement measurements, the correlation between tumor enhancement on cone beam computed tomography (CBCT) images and treatment response at 6 months in patients undergoing transarterial radioembolization (TARE) for liver metastases.</p></div><div><h3>Materials and Methods</h3><p>36 patients (56% male; median age 62.5 years) with 104 metastases were retrospectively included. Quantitative and qualitative enhancement of liver metastases were evaluated on CBCT images before TARE. Quantitative analysis consisted of lesion enhancement measurements (ROI HU lesion – ROI HU relative to inferior vena cava). Qualitative analysis consisted of subjective enhancement pattern analysis (diffuse, sparse, rim-like or non-enhancing). Morphologic tumor response was evaluated according to RECIST 1.1 criteria on follow-up CT or MR imaging.</p></div><div><h3>Results</h3><p>At a mean follow up of 6.5 ± 3.7 months, progressive disease (PD) was found in 4 patients, partial response (PR) in 11 and stable disease (SD) in 21. Relative lesion enhancement was significantly different between these groups (-37.5±154.2 HU vs. 103.8±93.4 vs. 181±144 HU in PD vs. SD vs. PR group, respectively; p&lt;0.01). ROC analysis of relative lesion enhancement to predict progressive disease showed an area under the curve of 0.86 (p&lt;0.01). For qualitative lesion enhancement analysis, no difference between groups was found.</p></div><div><h3>Conclusion</h3><p>Quantitative enhancement measurements derived from intraprocedural contrast enhanced CBCT may identify responders to TARE in patients with liver metastases.</p></div>","PeriodicalId":74676,"journal":{"name":"Research in diagnostic and interventional imaging","volume":"1 ","pages":"Article 100005"},"PeriodicalIF":0.0000,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772652522000059/pdfft?md5=22d0d2b8eddf9bfdc73351bc0e2cf2ee&pid=1-s2.0-S2772652522000059-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Research in diagnostic and interventional imaging","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772652522000059","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose

To investigate, by quantitative and qualitative enhancement measurements, the correlation between tumor enhancement on cone beam computed tomography (CBCT) images and treatment response at 6 months in patients undergoing transarterial radioembolization (TARE) for liver metastases.

Materials and Methods

36 patients (56% male; median age 62.5 years) with 104 metastases were retrospectively included. Quantitative and qualitative enhancement of liver metastases were evaluated on CBCT images before TARE. Quantitative analysis consisted of lesion enhancement measurements (ROI HU lesion – ROI HU relative to inferior vena cava). Qualitative analysis consisted of subjective enhancement pattern analysis (diffuse, sparse, rim-like or non-enhancing). Morphologic tumor response was evaluated according to RECIST 1.1 criteria on follow-up CT or MR imaging.

Results

At a mean follow up of 6.5 ± 3.7 months, progressive disease (PD) was found in 4 patients, partial response (PR) in 11 and stable disease (SD) in 21. Relative lesion enhancement was significantly different between these groups (-37.5±154.2 HU vs. 103.8±93.4 vs. 181±144 HU in PD vs. SD vs. PR group, respectively; p<0.01). ROC analysis of relative lesion enhancement to predict progressive disease showed an area under the curve of 0.86 (p<0.01). For qualitative lesion enhancement analysis, no difference between groups was found.

Conclusion

Quantitative enhancement measurements derived from intraprocedural contrast enhanced CBCT may identify responders to TARE in patients with liver metastases.

经动脉放射栓塞前用术中锥形束CT定量和定性评价肝转移作为治疗反应的预测因子
目的通过定量和定性增强测量,探讨经动脉放射栓塞(TARE)治疗肝转移患者6个月时锥形束计算机断层扫描(CBCT)图像肿瘤增强与治疗效果的相关性。材料与方法36例患者(男性56%;中位年龄62.5岁),回顾性纳入104例转移灶。通过TARE前的CBCT图像评估肝转移的定量和定性增强。定量分析包括病变增强测量(ROI HU病变- ROI HU相对于下腔静脉)。定性分析包括主观增强模式分析(弥漫性、稀疏性、边缘型或非增强)。根据RECIST 1.1标准对随访的CT或MR影像进行肿瘤形态反应评价。结果平均随访6.5±3.7个月,病情进展(PD) 4例,部分缓解(PR) 11例,病情稳定(SD) 21例。PD组、SD组、PR组相对病灶增强程度差异显著(分别为-37.5±154.2 HU、103.8±93.4 HU、181±144 HU);术中,0.01)。相对病灶增强预测疾病进展的ROC分析显示曲线下面积为0.86 (p<0.01)。在定性病灶增强分析中,两组间无差异。结论术中增强CBCT的定量增强测量可以识别肝转移患者对TARE的反应。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信